MedTrace Logo

Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)

NCT03199066 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2017-06-26

No results posted yet for this study

Summary

The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL).

The patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form.

Data quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.

Conditions

  • Non Hodgkin Lymphoma (NHL)

Sponsors & Collaborators

  • Czech Lymphoma Study Group

    lead OTHER

Principal Investigators

  • Marek Trneny, prof. MD · Charles University General Hospital, Prague, CZ

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-01
Primary Completion
2020-12-31
Completion
2027-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199066 on ClinicalTrials.gov